Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1981 3
1982 3
1983 1
1984 5
1985 1
1986 3
1987 1
1988 1
1989 1
1991 1
1993 1
1994 2
1995 1
1997 5
1998 7
1999 5
2000 7
2001 3
2002 7
2003 5
2004 10
2005 7
2006 9
2007 12
2008 12
2009 15
2010 12
2011 11
2012 9
2013 7
2014 12
2015 15
2016 19
2017 8
2018 13
2019 15
2020 10
2021 10
2022 4
2023 10
2024 5
2025 9
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

276 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Among authors: peron jm. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798579 Free PMC article. Clinical Trial.
TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.
Larrue H, D'Amico G, Olivas P, Lv Y, Bucsics T, Rudler M, Sauerbruch T, Hernandez-Gea V, Han G, Reiberger T, Thabut D, Vinel JP, Péron JM, García-Pagán JC, Bureau C. Larrue H, et al. Among authors: peron jm. J Hepatol. 2023 Sep;79(3):692-703. doi: 10.1016/j.jhep.2023.04.028. Epub 2023 May 2. J Hepatol. 2023. PMID: 37141993
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial.
Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC, Mody K, Gong J, Crysler OV, Sukeepaisarnjaroen W, Lipatov O, Morimoto M, Archambeaud I, Burgio V, Phuong LTT, Chao Y, Peron JM, Berres ML, Ko YJ, Ran D, Makowsky M, Negro A, Abou-Alfa GK. Lau G, et al. Among authors: peron jm. Hepatology. 2026 Mar 1;83(3):484-496. doi: 10.1097/HEP.0000000000001385. Epub 2025 May 16. Hepatology. 2026. PMID: 40384092 Free PMC article. Clinical Trial.
The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
Bureau C, Thabut D, Jezequel C, Archambeaud I, D'Alteroche L, Dharancy S, Borentain P, Oberti F, Plessier A, De Ledinghen V, Ganne-Carrié N, Carbonell N, Rousseau V, Sommet A, Péron JM, Vinel JP. Bureau C, et al. Among authors: peron jm. Ann Intern Med. 2021 May;174(5):633-640. doi: 10.7326/M20-0202. Epub 2021 Feb 2. Ann Intern Med. 2021. PMID: 33524293 Clinical Trial.
Hepatitis E virus.
Abravanel F, Lhomme S, Dubois M, Peron JM, Alric L, Kamar N, Izopet J. Abravanel F, et al. Among authors: peron jm. Med Mal Infect. 2013 Jul;43(7):263-70. doi: 10.1016/j.medmal.2013.03.005. Epub 2013 Apr 20. Med Mal Infect. 2013. PMID: 23608595 Review.
Hepatitis E, the neglected one.
Blasco-Perrin H, Abravanel F, Blasco-Baque V, Péron JM. Blasco-Perrin H, et al. Among authors: peron jm. Liver Int. 2016 Jan;36 Suppl 1:130-4. doi: 10.1111/liv.13014. Liver Int. 2016. PMID: 26725910 Review.
[Mixed odontogenic tumours].
Peron JM, Hardy H. Peron JM, et al. Rev Stomatol Chir Maxillofac. 2009 Sep;110(4):217-20. doi: 10.1016/j.stomax.2009.06.005. Epub 2009 Aug 5. Rev Stomatol Chir Maxillofac. 2009. PMID: 19660774 French.
Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.
Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, Mathurin P, Otal P, Cabarrou P, Péron JM, Vinel JP. Bureau C, et al. Among authors: peron jm. Gastroenterology. 2017 Jan;152(1):157-163. doi: 10.1053/j.gastro.2016.09.016. Epub 2016 Sep 20. Gastroenterology. 2017. PMID: 27663604 Free article. Clinical Trial.
Real-World Outcomes of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort.
Allaire M, Thiam EM, Amaddeo G, Bouattour M, Edeline J, Brusset B, Ziol M, Merle P, Blanc JF, Uguen T, Ganne N, Cattan S, Riachi G, Loustaud-Ratti V, Decaens T, Silvain C, Peron JM, Baron A, Pageaux GP, Oberti F, Anty R, Pascale A, Manfredi S, Bourliere M, Nousbaum JB, Heurgue A, Ollivier-Hourmand I, Lequoy M, Bronowicki JP, Villing AL, Ducournau G, Ganry O, Costentin C, Nguyen-Khac E. Allaire M, et al. Among authors: peron jm. Liver Int. 2025 Oct;45(10):e70337. doi: 10.1111/liv.70337. Liver Int. 2025. PMID: 40905621 Free PMC article.
Hepatitis E, what's the real issue?
Larrue H, Abravanel F, Péron JM. Larrue H, et al. Among authors: peron jm. Liver Int. 2020 Feb;40 Suppl 1:43-47. doi: 10.1111/liv.14351. Liver Int. 2020. PMID: 32077607 Review.
276 results